Top Dividend Stocks On The Chinese Exchange In July 2024

Amidst a backdrop of fluctuating global markets, Chinese stocks have shown resilience, buoyed by strong export figures despite domestic economic pressures. As investors seek stable returns amidst uncertainty, dividend-paying stocks on the Chinese exchange present a compelling option for those looking to balance growth with income in July 2024.

Top 10 Dividend Stocks In China

Name	Dividend Yield	Dividend Rating
Midea Group (SZSE:000333)	4.69%	★★★★★★
Changhong Meiling (SZSE:000521)	4.01%	★★★★★★
Wuliangye YibinLtd (SZSE:000858)	3.56%	★★★★★★
Inner Mongolia Yili Industrial Group (SHSE:600887)	4.58%	★★★★★★
Ping An Bank (SZSE:000001)	6.91%	★★★★★★
Huangshan NovelLtd (SZSE:002014)	5.91%	★★★★★★
China South Publishing & Media Group (SHSE:601098)	4.65%	★★★★★★
Chacha Food Company (SZSE:002557)	3.62%	★★★★★★
HUAYU Automotive Systems (SHSE:600741)	4.76%	★★★★★★
Zhejiang Jiaxin SilkLtd (SZSE:002404)	5.78%	★★★★★★

Click here to see the full list of 255 stocks from our Top Chinese Dividend Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Hubei Jumpcan Pharmaceutical (SHSE:600566)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Hubei Jumpcan Pharmaceutical Co., Ltd. is a company based in China that focuses on the research, development, manufacturing, and sale of traditional Chinese medicines, western medicines, and health products, with a market capitalization of approximately CN¥30.41 billion.

Operations: Hubei Jumpcan Pharmaceutical Co., Ltd. generates its revenue primarily from the sale of traditional Chinese medicines, western medicines, and health products.

Dividend Yield: 3.9%

Hubei Jumpcan Pharmaceutical has displayed a mixed performance in its dividend offerings. Despite an increased dividend, the company has only been distributing dividends for 9 years with a history of volatility. Its dividends are supported by earnings and cash flows, with payout ratios at 39.8% and 37.8% respectively, indicating reasonable coverage. Recent financials show strong earnings growth with net income rising to CNY 845.27 million from CNY 676.76 million year-over-year as of Q1 2024, reflecting a robust financial position that could support future dividends despite past inconsistencies.

• Unlock comprehensive insights into our analysis of Hubei Jumpcan Pharmaceutical stock in this dividend report.
• Our valuation report unveils the possibility Hubei Jumpcan Pharmaceutical's shares may be trading at a discount.

China Pacific Insurance (Group) (SHSE:601601)

Simply Wall St Dividend Rating: ★★★★★☆

Overview: China Pacific Insurance (Group) Co., Ltd. offers a range of insurance products to individual and institutional clients across the People’s Republic of China, with a market capitalization of approximately CN¥257.48 billion.

Operations: China Pacific Insurance (Group) Co., Ltd. generates its revenue primarily through the sale of insurance products across China.

Dividend Yield: 3.4%

China Pacific Insurance has shown a mixed track record in dividend reliability, with increases over the past decade but also volatility. Its dividend yield of 3.42% ranks well in China's top quartile, supported by a low payout ratio of 35.9% and an even lower cash payout ratio of 7.3%, indicating strong coverage by both earnings and cash flows. Recently, it confirmed an annual dividend of RMB 1.02 per share at its AGM on June 6, 2024, underscoring its commitment to returning value to shareholders despite past fluctuations in payments.

• Get an in-depth perspective on China Pacific Insurance (Group)'s performance by reading our dividend report here.
• According our valuation report, there's an indication that China Pacific Insurance (Group)'s share price might be on the cheaper side.

Wuhan Keqian BiologyLtd (SHSE:688526)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Wuhan Keqian Biology Co., Ltd. specializes in the R&D, production, sales, and provision of technical services for veterinary biological products in China, with a market cap of approximately CN¥6.43 billion.

Operations: Wuhan Keqian Biology Co., Ltd. generates its revenue primarily from the veterinary biological products sector, totaling CN¥989.49 million.

Dividend Yield: 3.1%

Wuhan Keqian BiologyLtd has experienced a decline in sales and net income in the first quarter of 2024, with revenues dropping to CNY 204.93 million from CNY 279.51 million year-over-year, and net income falling to CNY 87.23 million from CNY 135.54 million. Despite this downturn, the company maintains a reasonable dividend coverage with a payout ratio of 58.2% and cash payout ratio of 50.2%, indicating that current dividends are well-supported by earnings and cash flows. However, its dividend history is marked by volatility and inconsistency over its short three-year distribution period, which might concern investors looking for stable returns.

• Take a closer look at Wuhan Keqian BiologyLtd's potential here in our dividend report.
• The analysis detailed in our Wuhan Keqian BiologyLtd valuation report hints at an deflated share price compared to its estimated value.

Taking Advantage

• Unlock our comprehensive list of 255 Top Chinese Dividend Stocks by clicking here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com